Polymorphic effects of cavinton: experimental and clinical evidence

Close metadata

Recommended articles:

The use of Mexidol in patients with mild (moderate) cognitive impairment: results of a meta-analysis. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(1):82-88

Laser fluorescence spectroscopy and navigation in surgical treatment of spinal tumors: a systematic review. Burdenko's Journal of Neurosurgery. 2024;(1):109-114

Localized scleroderma: etiology, pathogenesis, clinical manifestations, difficulties of diagnosis and therapy. Russian Journal of Clinical Dermatology and Venereology. 2024;(1):12-18

Multi-center open comparative randomized study of efficacy and safety of Akatinol Memantine 20 mg (single-doses) vs Akatinol Memantine 10 mg (double-doses) in patients with vascular dementia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(2):69-77

Short-term outcomes of mechanical and hand-sewn laparoscopic one-anastomosis mini-gastric bypass. Pirogov Russian Journal of Surgery. 2024;(4):29-37

Development of professional activities of healthy lifestyle specialists without medical education. Russian Journal of Preventive Medicine. 2024;(4):116-123

Long-term follow-up of adult patients with serial and status course of epileptic seizures. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):63-68

Results of a pilot study of the structure and evaluation of the therapy for chronic sleep disorders in comorbid patients with chronic cerebral ischemia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):118-126

Efficacy of different postural control training in elderly people with chronic cerebral ischemia. Regenerative Biotechnologies, Preventive, Digital and Predictive Medicine. 2024;(2):42-48

Effectiveness of spinal traction in degenerative spine diseases. (A literature review). Problems of Balneology, Physiotherapy and Exercise Therapy. 2024;(4):60-69

Disturbances of short-term memory are the most early and frequent alterations of cognitive functions in multiple sclerosis (MS). We have conducted a complex neuropsychological and brain MRI study in patients with MS. The disturbances of memory were found in MS patients regardless of disease type and duration. The central pathophysiological process of the development of cognitive disturbances in MS is the lesion of projection, commissural and long association fibers that results in the disturbances of integrative brain activity and activation of the cortex in deep structures, first of all, in the thalamus.

Keywords:

vinpocetine (cavinton)

efficacy

safety

chronic brain ischemia

vinpocetine (cavinton)

efficacy

safety

chronic brain ischemia

Authors:

Kasatkin D.S.

Poliklinika #5, Iaroslavl'

List of references:

Kiss B., Karpati E. Mechanism of action of vinpocetine. Acta Pharm Hung 1996; 66: 213-224.
Burtsev E., Savkov V., Shprakh V. et al. 10-year experience with using Cavinton in cerebrovascular disorders. J Nevropatol Psyhiat 1992; 92: 56-60.
Bereczki D., Fekete I. A systematic review of vinpocetine therapy in acute ischaemic stroke. Eur J Clin Pharmacol 1999; 55: 349-352.
Cervenka F., Jahodár L. Plant metabolites as nootropics and cognitives. Ceska Slov Farm 2006; 55: 5: 219-229.
Thal L.J., Salmon D.P., Lasker B. et al. The safety and lack of efficacy of vinpocetine in Alzheimer’s disease. J Am Geriat Soc 1989; 37: 515-520.
Karpati E., Biro K., Kukorelli T. Investigation of vasoactive agents with indole skeletons at Richter Ltd. Acta Pharm Hung 2002; 72: 25-36.
Kim D., Rybalkin S.D., Pi X. et al. Upregulation of phosphodiesterase 1A1 expression is associated with the development of nitrate tolerance. Circulation 2001; 104: 19: 2338-2343.
Chiu P.J., Tetzloff G., Ahn H.S. et al. Comparative effects of vinpocetine and 8-Brcyclic GMP on the contraction and 45Cafluxes in the rabbit aorta. Am J Hypertens 1988; 1: 262-268.
Osawa M., Maruyama S. Effects of TCV-3B (vinpocetine) on blood viscosity in ischemic cerebrovascular diseases. Ther Hung 1985; 33: 7-12.
Hayakawa M. Effect of vinpocetine on red blood cell deformabilitty in stroke patients. Arzneim-Forschung 1992; 42; 4: 425-427.
Kuzuya F. Effects of vinpocetine on platelet aggregability and erythrocyte deformability. Geriat Med 1982; 20: 151-156.
Imamoto T., Tanabe M., Shimamoto N. et al. Cerebral circulatory and cardiac effects of vinpocetine and its metabolite, apovincaminic acid, in anaesthetized dogs. Arzneimittelforschung 1984; 34: 161-169.
Miyazaki M. The effect of cerebral vasodilator, vipocetine, on cerebral vascular resistance evaluated by the Doppler ultrasonic technique in patients with cerebrovascular diseases. Angiol 1995; 46: 53-58.
Shibota M., Kakihana M., Nagaoka A. The effect of vinpocetine on brain glucose uptake in mice. Nippon Yakurigaku Zasshi 1982; 80: 221-224.
Solti F. Cavinton, a new cerebral vasodilator. Ther Hung 1979; 27: 1: 15-16.
Solti F., Iskum M., Czako E. Effect of ethyl apovincaminate on cerebral circulation. Studies in patients with obliterative cerebral arterial disease. Arzneim-Forschung 1976; 26: 1945-1947.
Lebedeva N.V. Znachenie preparata kavinton v lechenii bol'nykh s ostroi i khronicheskoi sosudistoi mozgovoi nedostatochnost'yu. V kn.: Kavinton i vozmozhnosti ego primeneniya v meditsinskoi praktike. M 1986; 29-35.
Tamaki N., Kusunoki T., Matsumoto S. The effect of vinpocetine on cerebral blood flow in patients with cerebrovascular disorders. Ther Hung 1985; 33: 13-21.
Tohgi H., Sasaki K., Chiba K. et al. Effect of vinpocetine on oxygen release of hemoglobin and erythrocyte organic polyphosphate concentrations in patients with vascular dementia of the Binswanger type. Arzneimittelforschung 1990; 40: 6: 640-643.
Szakall Sz., Boros L., Balkay L. Cerebral effects of a single dose of intravenouse vinpocetine in chronic stroke patients: a PET study. J Neuroimagine 1998; 8: 197-204.
Szilagyi G., Nagy Z., Balkay L. et al. Effects of vinpocetine on the redistribution of cerebral blood flow and glucose metabolism in chronic ischemic stroke patients: a PET study. Neurol Sci 2005; 229-230: 1: 275-284.
Bonoczk P., Gulyas B., Adam-Vizi V. et al. Role of sodium channel inhibition in neuroprotection: effect of vinpocetine. Brain Res Bull 2000; 53: 245-254.
Molnar P., Erdo S.L. Vinpocetine is as potent as phenytoin to block voltage-gated Na+ channels in rat cortical neurons. Eur J Pharmacol 1995; 273: 303-306.
Urenjak J., Obrenovitch T.P. Pharmacological modulation of voltage-gated Na+ channels: a rational and effective strategy against ischemic brain damage. Pharmacol Rev 1996; 48: 21-67.
Santos M.S., Duarte A.I., Moreira P.I. et al. Synaptosomal response to oxidative stress: effect of vinpocetine. Free Radic Res 2000; 32: 1: 57-66.
Stolc S. Indole derivatives as neuroprotectants. Life Sci 1999; 65: 1943-1950.
Gabryel B., Adamek M., Pudelko A. et al. Piracetam and vinpocetine exert cytoprotective activity and prevent apoptosis of astrocytes in vitro in hypoxia and reoxygenation. Neurotoxicology 2002; 23: 19-31.
Horvath B., Marton Z., Halmosi R. et al. In vitro antioxidant properties of pentoxifylline, piracetam, and vinpocetine. Clin Neuropharmacol 2002; 25: 37-42.
Miyamoto M., Murphy T.H., Schnaar R.L. et al. Antioxidants protect against glutamateinduced cytotoxicity in a neuronal cell line. J Pharmacol Exp Ther 1989; 250: 1132-1140.
Nyakas C., Felszeghy K., Szaboґ R. et al. Neuroprotective Effects of Vinpocetine and its Major Metabolite Cis-apovincaminic Acid on NMDA-Induced Neurotoxicity in a Rat Entorhinal Cortex Lesion Model. CNS Neurosci Ther 2009; 15: 89-99.
Taґrnok K., Kiss E., Luiten P.G.M. et al. Effects of Vinpocetine on mitochondrial function and neuroprotection in primary cortical neurons. Neurochemistry International 2008; 53: 289-295.
Engert F., Bonhoeffer T. Dendritic spine changes associated with hippocampal long-term synaptic plasticity. Nature 1999; 399: 66-70.
Maletic-Savatic M., Malinow R., Svoboda K. Rapid dendritic morphogenesis in CA1 hippocampal dendrites induced by synaptic activity. Science 1999; 283: 1923-1927.
Hindmarch I., Fuchs H.H., Erzigkeit H. Efficacy and tolerance of vinpocetine in ambulant patients suffering from mild to moderate organic psychosyndromes. Int Clin Psychopharmacol 1991; 6: 31-43.
Fischer M., Kaech S., Knutti D. et al. Rapid actin-based plasticity in dendritic spines. Neuron 1998; 20: 847-854.
Lombillo V.A., Stewart R.J., McIntosh J.R. Minus-end-directed motion of kinesin-coated microspheres driven by microtubule depolymerization. Nature 1995; 373: 161-164.
Kiss B., Szporny L. On the Possible Role of Central Monoaminergic Systems in the Central Nervous System Actions of Vinpocetine. Drug Devel Res 1988; 14: 263-279.
Gaal L., Molnar P. Effect of vinpocetine on noradrenergic neurons in rat locus coeruleus. Eur J Pharmacol 1990; 187: 3: 537-539.
Lipani G. A double-blind parallel group placebo controlled evaluation of the safety and efficacy of vinpocetine in the treatment of patients with chronic vascular or degenerative senile cerebral dysfunction. Garibaldi Provincial General Hospital. Catania, Italy: Protocol 1984; 84-175.
Peruzza M., DeJakobis M. A double-blind placebo controlled evaluation of the efficacy and safety of vinpocetine in the treatment of patients with chronic vascular or degenerative senile cerebral dysfunction. Adv Ther 1986; 3: 4: 201-209.
Manconi E., Binaghi E., Pitzus F. A double-blind clinical trial of vinpocetine in the treatment of cerebral insufficiency of vascular and degenerative origin. Cur Ther Res 1986; 40: 4: 702-709.
Fenzl E., Apechea M., Schaltenbrand R. et al. Long-term study concerning tolerance and efficacy of vinpocetine in elderly patients suffering from a mild to moderate organic psychosyndrome. In: Senile demetias: early detection. Ed. A. Bes et al. 1986; 580-585.
Balestreri R., Fontana L., Astengo E. A double-blind placebo controlled evaluation of the safety and efficacy of vinpocetine in the treatment of patients with chronic vascular senile cerebral dysfunction. J Am Geriat Soc 1987; 35: 425-430.
Fuchs H.H., Erzigkeit H. Efficacy and tolerance of vinpocetine in dementia. Psychopharmacology 1988; 96: Suppl: Abstr 25: 43.08.
Blaha L., Erzigkeit H., Adamczyk A. et al. Clinical evidence of the effectiveness of vinpocetine in the treatment of organic psychosyndrome. Human Psychopharmacol 1989; 4: 103-111.
Nagy Z., Vargha P., Kovacs L. et al. Metaanalysis of cavinton. Praxis 1998; 7: 63-68.
Szobor A., Klein M. Ethyl apovincaminate therapy in neurovascular disease. Arzneim-Forsch 1976; 26: 10: 1984-1989.
Perényi T., Buday G., Kerkovits G. et al. The effect of Cavinton on patients susceptible to arrhythmia studied by ECG monitoring. Orv Hetil 1983; 124: 47: 2875-2876.
Ebi O. Open-labeled phase III clinical trials with vinpocetine in Japan. Ther Hung 1985; 33: 1: 41-49.
Farsang C., Kertész G., Bánki M.C. et al. Effect of two years‘ Cavinton treatment on the ECG. Ther Hung 1987; 35: 3: 125-128.
Chukanova E.I. Opyt dlitel'nogo kursovogo primeneniya neirometabolicheskikh preparatov v lechenii khronicheskoi tserebral'noi sosudistoi nedostatochnosti (farmakoekonomicheskie aspekty). Kachestv klin prakt 2003; 4: 1-5.

Close metadata